奥布替尼治疗多种免疫抑制剂无效且合并感染的自身免疫性溶血性贫血1例

申清云; 黄彬涛; 高大

doi:10.13201/j.issn.1004-2806.2023.01.014

奥布替尼治疗多种免疫抑制剂无效且合并感染的自身免疫性溶血性贫血1例

- 内蒙古医科大学附属医院血液内科(呼和浩特，010059)
基金项目:
内蒙古自然科学基金(No：2019MS08028)

详细信息

通讯作者: 黄彬涛，E-mail：huangbintao1979@sina.com

中图分类号: R556.6

收稿日期: 2022-04-03

刊出日期: 2023-01-01

A case of autoimmune hemolytic anemia with infection and no response to multiple immunosuppressants treated with orelabrutinib

- Department of Hematology, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot, 010059, China

More Information

Corresponding author: HUANG Bintao, E-mail: huangbintao1979@sina.com

Received Date: 03 April 2022

Publish Date: 01 January 2023

摘要

摘要: 自身免疫性溶血性贫血(AIHA)是一种罕见的异质性疾病，尽管对其发病机制和治疗的研究非常丰富，但仍有许多问题有待解决。难治性或复发性AIHA患者仍然是目前临床治疗的难点，临床对于针对AIHA的新药物的需求更加迫切。布鲁顿酪氨酸激酶(BTK)在B细胞的发育和功能中起到关键作用，被认为是治疗B细胞恶性肿瘤和自身免疫性疾病的潜在靶点。目前国内外关于BTK抑制剂治疗AIHA的报道罕见，现报道1例奥布替尼有效治疗难治性AIHA的病例，并对相关文献进行复习。
- 自身免疫性溶血性贫血 /
- BTK抑制剂
Abstract: Autoimmune hemolytic anemia(AIHA) is a rare heterogeneous disease, although the study of its pathogenesis and treatment are very abundant, there are still many problems to be solved. For refractory or relapsed AIHA cases, the clinical demand for new drugs targeting AIHA is more urgent. Bruton tyrosine kinase(BTK) plays a key role in the development and function of B cells and is considered as a potential target for the treatment of B cell malignancies and autoimmune diseases. At present, there are few reports on the treatment of AIHA by BTK inhibitors at home and abroad. It reports a case of orelabrutinib treatment of AIHA and review relevant literatures.
- autoimmune hemolytic anemia /
- BTK inhibitors

HTML全文

图 1 患者奥布替尼治疗后HGB、TBil、LDH变化

下载: 全尺寸图片幻灯片

参考文献(32)

[1]	方力维, 潘虹, 施均. 伊布替尼治疗复发/难治原发性自身免疫性溶血性贫血二例——探索性研究[J]. 中华血液学杂志, 2020, 41(5): 412-416.
[2]	Hill A, Hill QA. Autoimmune hemolytic anemia[J]. Hematology Am Soc Hematol Educ Program, 2018, 2018(1): 382-389. doi: 10.1182/asheducation-2018.1.382
[3]	Dhillon S. Orelabrutinib: First Approval[J]. Drugs, 2021, 81(4): 503-507. doi: 10.1007/s40265-021-01482-5
[4]	Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting[J]. Blood Rev, 2020, 41(2): 100648.
[5]	Piatek CI, Bocian H, Algaze S, et al. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia[J]. Acta Haematol, 2020, 143(3): 244-249. doi: 10.1159/000501538
[6]	Murphy S, LoBuglio AF. Drugtherapy of autoimmune hemolytic anemia[J]. Semin Hematol, 1976, 13(4): 323-334.
[7]	Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on single-center experience with 60 patients[J]. Am J Hematol, 2014, 89(9): E150-E155. doi: 10.1002/ajh.23767
[8]	Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase Ⅲ randomized trial comparing glucocorticoid monotherapy versus glucocorticoid andrituximab in patients with autoimmune haemolytic anaemia[J]. Br J Haematol, 2013, 163(3): 393-399. doi: 10.1111/bjh.12541
[9]	Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximabfor warm auto-immune hemolytic anemia in adults(the RAIHA study)[J]. Am J Hematol, 2017, 92(1): 23-27. doi: 10.1002/ajh.24570
[10]	Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, et al. Autoimmune hemolytic anemia: current knowledge and perspectives[J]. Immun Ageing, 2020, 17(1): 38. doi: 10.1186/s12979-020-00208-7
[11]	张静, 王素玲, 乔芳, 等. 自身免疫性溶血性贫血患者抗-LW抗体和自身抗-D抗体鉴定及输血策略[J]. 临床血液学杂志, 2022, 35(10): 748-751. doi: 10.13201/j.issn.1004-2806.2022.10.013 http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=a355ba71-9b05-4f3b-b2d4-483e1c41033b
[12]	Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients[J]. Blood, 2014, 124(19): 2930-2936. doi: 10.1182/blood-2014-06-583021
[13]	Phillips J, Henderson AC. Hemolytic Anemia: Evaluation and Differential Diagnosis[J]. Am Fam Physician, 2018, 98(6): 354-361.
[14]	Coon WW. Splenectomy in the treatment of hemolytic anemia[J]. Arch Surg, 1985, 120(5): 625-628. doi: 10.1001/archsurg.1985.01390290099017
[15]	Patel NY, Chilsen AM, Mathiason MA, et al. Outcomes and complications after splenectomy for hematologicdisorders[J]. Am J Surg, 2012, 204(6): 1019-1020.
[16]	Barcellini W, Fattizzo B. How I treat warm autoimmune hemolytic anemia[J]. Blood, 2021, 137(10): 1283-1294. doi: 10.1182/blood.2019003808
[17]	Brodsky RA. Warm Autoimmune Hemolytic Anemia[J]. N Engl J Med, 2019, 381(7): 647-654. doi: 10.1056/NEJMcp1900554
[18]	Chen M, Zhuang J, Yang C, et al. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia[J]. Ann Hematol, 2020, 99(5): 1141-1143. doi: 10.1007/s00277-020-03976-w
[19]	Barcellini W, Zaninoni A, Fattizzo B, et al. Predictors of refractoriness to therapy and health care resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers[J]. Am J Hematol, 2018, 93(9): E243-E246. doi: 10.1002/ajh.25212
[20]	Rattarittamrong E, Eiamprapai P, Tantiworawit A, et al. Clinical characteristics and long-termout comes of warm-type autoimmune hemolytic anemia[J]. Hematology, 2016, 21(6): 368-374. doi: 10.1080/10245332.2016.1138621
[21]	Fattizzo B, Zaninoni A, Nesa F, et al. Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias[J]. Am J Hematol, 2015, 90(8): E149-E151. doi: 10.1002/ajh.24047
[22]	Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia[J]. Expert Rev Clin Immunol, 2018, 14(10): 857-872. doi: 10.1080/1744666X.2018.1521722
[23]	Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton's tyrosine kinase(Btk): Function, regulation, and transformation with special emphasis on the PH domain[J]. Immunol Rev, 2009, 228(4): 58-73.
[24]	Takata M, Kurosaki T. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2[J]. J Exp Med, 1996, 184(1): 31-40. doi: 10.1084/jem.184.1.31
[25]	Mohamed AJ, Nore BF, Christensson B, et al. Signaling of Bruton's tyrosine kinase, Btk[J]. Scand J Immunol, 1999, 49(2): 113-118. doi: 10.1046/j.1365-3083.1999.00504.x
[26]	Wen TY, Wang JS, Shi YK, et al. Inhibitors targeting Bruton's tyrosine kinase in cancers: Drug development advances[J]. Leukemia, 2021, 35(2): 312-332. doi: 10.1038/s41375-020-01072-6
[27]	Crofford LJ, Nyhoff LE, Sheehan JH, et al. The role of bruton's tyrosine kinase in autoimmunity and implications for therapy[J]. Expert Rev Clin Immunol, 2016, 12(7): 763-773. doi: 10.1586/1744666X.2016.1152888
[28]	Feng YF, Duan WM, Cu XC, et al. Bruton's tyrosine kinase(BTK)inhibitors in treating cancer: A patentreview(2010-2018)[J]. Expert Opin Ther Pat, 2019, 29(4): 217-241. doi: 10.1080/13543776.2019.1594777
[29]	Liang CY, Tian DN, Ren XD, et al. The development of Bruton's Tyrosine Kinase(BTK)inhibitors from 2012 to 2017: A mini-review[J]. Eur J Med Chem, 2018, 151(1): 315-326.
[30]	Brullo C, Villa C, Tasso B, et al. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective[J]. Int J Mol Sci, 2021, 22(14): 7641. doi: 10.3390/ijms22147641
[31]	Liu J, Chen C, Wang D, et al. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase(BTK): Current development[J]. Eur J Med Chem, 2021, 217(2): 113329.
[32]	Lorenzo-Vizcaya A, Fasano S, Isenberg DA. Bruton's tyrosine kinase inhibitors: A new therapeutic target for the treatment of SLE?[J]. Immunotargets Ther, 2020, 9(3): 105-110.